Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genprex, Inc. (NASDAQ: GNPX) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a clinical-stage gene therapy company, Genprex uses these filings to describe its oncology and diabetes pipelines, financing activities, and Nasdaq listing status.
Key documents include registration statements such as Form S-1 and Form S-3, where Genprex outlines its business overview, risk factors, and details of equity offerings and warrant structures. These filings describe the company’s focus on Reqorsa Gene Therapy (quaratusugene ozeplasmid) for non-small cell and small cell lung cancer, the Oncoprex Delivery System, and the GPX-002 diabetes gene therapy program using AAV delivery of Pdx1 and MafA genes to the pancreas.
Investors can also review Form 8-K current reports that document material events. Recent 8-Ks discuss registered direct offerings and concurrent private placements, at-the-market program updates, new patents and patent intentions around Reqorsa combinations with PD-1 and PD-L1 antibodies, additions of clinical trial sites for Acclaim-1 and Acclaim-3, and communications with Nasdaq regarding minimum bid price and stockholders’ equity requirements.
On Stock Titan, AI-powered tools summarize lengthy prospectuses and current reports, helping readers quickly identify sections related to gene therapy mechanisms, clinical trial design, regulatory designations, and capital-raising terms. As new filings appear on EDGAR, they are reflected here in near real time, giving users an organized view of Genprex’s regulatory history, financing transactions, and disclosures relevant to GNPX stock.
Genprex, Inc. reported new patent progress for its lead gene therapy, REQORSA (quaratusugene ozeplasmid), in combination with checkpoint inhibitor drugs. The U.S. Patent and Trademark Office issued a notice of allowance for a patent covering REQORSA with PD-L1 antibodies such as Tecentriq, and the European Patent Office issued a notice of allowance for a patent covering REQORSA with PD-1 antibodies. Both patents will expire in 2037 at the earliest.
The company already holds patents for REQORSA with PD-L1 antibodies in Korea and for REQORSA with PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Korea and Singapore, and is pursuing additional applications in Europe, Canada, Brazil, China and Israel that could apply to its Acclaim-3 trial. Acclaim-3 is a Phase 1/2 study of REQORSA plus Genentech’s Tecentriq as maintenance therapy for extensive stage small cell lung cancer, and this trial has received FDA Fast Track and Orphan Drug designations.
Genprex, Inc. reported results of its 2025 annual stockholder meeting. Stockholders approved an amended and restated 2018 Equity Incentive Plan, adding authorization for an additional 6,500,000 shares of common stock, extending the plan term to June 30, 2035, and removing outdated tax-driven performance compensation provisions. They re-elected Class II director William R. Wilson, Jr. and ratified WithumSmith+Brown, PC as auditor for the year ending December 31, 2025.
Investors gave advisory approval to named executive officer pay and formally approved the amended equity plan. They also approved, under Nasdaq Listing Rule 5635(d), a potential issuance of more than 20% of outstanding common stock under the company’s purchase agreement with Lincoln Park Capital Fund, LLC. In addition, stockholders authorized a reverse stock split of issued common shares at a ratio between 1-for-10 and 1-for-50, which the board may implement at its discretion any time before December 31, 2026.
Genprex announced positive preclinical research results for GPX-002, its diabetes gene therapy drug candidate, presented at the 2025 American Diabetes Association Scientific Sessions. The research demonstrated significant breakthroughs in treating Type 1 diabetes using gene therapy.
Key findings include:
- Successfully converted alpha cells into insulin-secreting beta-like cells in animal models, maintaining improved glucose control for three months
- Utilized rAAV delivery system through pancreatic duct infusion to deliver Pdx1 and MafA genes
- Non-human primates showed improved glucose tolerance and reduced insulin requirements one month post-treatment
- Temporary immunosuppression using rituximab, rapamycin, and steroids proved effective for 3 months, with ongoing studies evaluating 6-month protocols
The research suggests GPX-002 could potentially revolutionize diabetes treatment through cell transdifferentiation, though continued studies are needed to optimize immunosuppression protocols and evaluate long-term efficacy in both Type 1 and Type 2 diabetes models.
Genprex announced positive preclinical data for GPX-002, its diabetes gene therapy candidate, presented at the 2025 ADA Scientific Sessions. The research showcased a novel non-viral delivery approach using lipid nanoparticles (LNPs), marking a significant advancement in diabetes treatment technology.
Key findings include:
- Successful testing of 9 LNPs with patented LipexSil® lipids, demonstrating efficient cell transfection in mouse Islets of Langerhans
- ALX-184 LNP showed particular promise in crossing the pancreatic membrane and effectively delivering mRNA payloads
- The non-viral delivery system potentially enables repeat dosing without immunosuppression, a significant advantage over traditional AAV delivery methods
This research runs parallel to Genprex's ongoing AAV construct studies, representing a strategic expansion of their diabetes program. The company believes these findings provide crucial proof of concept for advancing their Type 1 diabetes treatment approach, though they caution that all forward-looking statements are subject to risks and uncertainties.